Effect of trimazosin on hemodynamics in chronic heart failure

Publisher Website
Google Scholar
Abstract
The effect of the oral vasodilator trimazosin on hemodynamics in 16 patients with chronic left ventricular failure was compared with placebo in a double‐blind, randomized study. Eight patients received trimazosin 100 to 300 mg, and 8 received placebo. Over the 6‐hr period after medication trimazosin caused no significant change in heart rate, stroke work index, or pulmonary vascular resistance, but there were significant reductions in mean arterial pressure (p < 0.05), mean right atrial pressure (p < 0.01), mean pulmonary artery pressure (p < 0.01), mean pulmonary capillary wedge pressure (p < 0.01), and systemic vascular resistance (p < 0.01), and significant increases in stroke index (p < 0.05) and cardiac index (p < 0.05). None of 8 patients improved after placebo, whereas 5 of 8 patients (63%) had a good or excellent hemodynamic response after trimazosin (p = 0.006). Four of 4 patients who received 300 mg of trimazosin had a good or excellent response. Trimazosin is a long‐acting orally effective vasodilator which improves ventricular function in patients with left ventricular failure.